SEQUOIA: Zanubrutinib Holds Up in CLL’s Toughest Age GroupByAlessandra Tedeschi, MDJune 28th 2026SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.